Business Context and Reporting Period
Instil Bio, Inc. (TIL) is a clinical-stage biopharmaceutical company focused on developing novel therapies for diseases with significant unmet medical needs. This Form 10-Q covers the quarterly period ended September 30, 2024. The Company operates as a single segment and is classified as an emerging growth company and a smaller reporting company. In August 2024, the Company's subsidiary, SynBioTx, in-licensed bispecific antibodies (SYN-2510 and SYN-27M) from ImmuneOnco Biopharmaceuticals (Shanghai) Inc. for development outside of Greater China.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(23,021) | $(67,432) | $(62,240) | $(143,162) |
| Net Loss Per Share (Basic/Diluted) | $(3.54) | $(10.37) | $(9.57) | $(22.01) |
| Cash, Cash Equivalents, and Restricted Cash | $6,663 | $10,146 | $6,663 | $10,146 |
| Marketable Securities & Long-Term Investments | $116,247 | $164,322 | $116,247 | $164,322 |
| Total Liquid Assets | $122,910 | $174,468 | $122,910 | $174,468 |
| Loan Payable (Principal) | $82,837 | $82,837 | $82,837 | $82,837 |
| Accumulated Deficit | $(643,221) | $(568,056) | $(643,221) | $(568,056) |
Note: The Company has no product revenue. Other rental income of $1.493 million was recognized in Q3 2024 related to the lease of the Tarzana facility to AstraZeneca, recorded as "Other rental income" rather than revenue.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased significantly to $23.0 million in Q3 2024 from $67.4 million in Q3 2023. This improvement is primarily driven by a $43.9 million decrease in restructuring and impairment charges, largely due to the absence of the $41.5 million impairment of the Tarzana manufacturing facility recorded in the prior year.
- Operating Expenses: Total operating expenses dropped to $23.6 million in Q3 2024 from $66.7 million in Q3 2023. Research and Development (R&D) expenses fell to $0.6 million from $8.5 million due to the discontinuation of ITIL-168 clinical manufacturing activities and reduced headcount. However, In-Process Research and Development (IPR&D) expenses increased by $10.0 million due to the upfront payment for the ImmuneOnco license.
- Liquidity: Total liquid assets (cash, equivalents, and investments) decreased to $122.9 million from $174.5 million year-over-year, reflecting operating cash burn and the $10 million IPR&D payment, partially offset by interest income and maturities of marketable securities.
- Restructuring: The Company continues to execute a restructuring plan ("2024 Plan") involving the closure of UK manufacturing and clinical operations. Restructuring charges for the nine months ended September 30, 2024, were $7.1 million compared to $71.8 million in the prior year period.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring net losses for the foreseeable future. Based on current operating plans, the Company believes its existing cash and investments ($122.9 million) are sufficient to fund operations beyond 2026. This estimate assumes the successful sale or refinancing of the Tarzana facility, which is currently leased to AstraZeneca.
- Strategic Focus: The Company is pivoting to focus on the development of SYN-2510 (a PD-L1xVEGF bispecific antibody) and SYN-27M (an anti-CTLA-4 antibody) in-licensed from ImmuneOnco. Clinical trials for these candidates are being conducted by ImmuneOnco in China.
- Key Risks:
- Capital Needs: The Company requires substantial additional funding to meet financial obligations and pursue business objectives. Failure to raise capital could force delays or curtailment of operations.
- Regulatory Uncertainty: The Company has no prior experience completing clinical trials or obtaining regulatory approvals. Data from trials conducted in China may not be accepted by the FDA without additional U.S.-based trials.
- Third-Party Dependence: The Company relies on ImmuneOnco for manufacturing and clinical development of its lead candidates and on third parties for other development activities.
- Restructuring Costs: Additional charges of up to $0.5 million are expected in 2024 related to the 2024 Plan.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $122.9 million in liquid assets to fund operations beyond 2026, specifically assessing the risk if the Tarzana facility sale or refinancing does not materialize.
- Debt Covenants: Confirm continued compliance with the $85.0 million consolidated net worth and liquid assets covenants associated with the $82.8 million construction loan.
- IPR&D Expenditure: Review the terms of the ImmuneOnco collaboration, including the $10 million upfront payment and potential future milestones totaling up to $2.1 billion, to assess future cash outflow obligations.
- Restructuring Completion: Monitor the completion of the UK workforce reduction and facility closures to ensure no unexpected additional impairment charges arise.
- Regulatory Path: Evaluate the strategy for obtaining FDA approval for SYN-2510 given the reliance on clinical data generated in China by a third party.